PMS-PANTOPRAZOLE TABLET (DELAYED-RELEASE)

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM)

Saadav alates:

PHARMASCIENCE INC

ATC kood:

A02BC02

INN (Rahvusvaheline Nimetus):

PANTOPRAZOLE

Annus:

20MG

Ravimvorm:

TABLET (DELAYED-RELEASE)

Koostis:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

PROTON-PUMP INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0133229002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2008-06-03

Toote omadused

_pms-PANTOPRAZOLE Product Monograph _
_Page 1 of 50_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-PANTOPRAZOLE
Pantoprazole Sodium Delayed-Release Tablets
Delayed-Release Tablets, 20 mg and 40 mg pantoprazole (as pantoprazole
sodium), Oral
House Standard (20 mg) & USP (40 mg)
Proton Pump Inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
Submission Control Number: 265478
Date of Initial Authorization:
FEB 7, 2007
Date of Revision:
DEC 6, 2022
_pms-PANTOPRAZOLE Product Monograph _
_Page 2 of 50_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
03/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
......................................................................................................................4
1.1
Pediatrics (<18 years of age)
....................................................................................4
1.2
Geriatrics.................................................................................................................4
2
CONTRAINDICATIONS
.........................................................................................................4
4
DOSAGE AND ADMINISTRATION
........................................................................................5
4.1
Dosing Considerations
.............................................................................................5
4.2
Recommended Dose and Dosage
Adjustment...........................................................5
4.4
Administration................................